ClinicalTrials.gg
Status unknownNCT02092532RIVALUpdated Oct 15, 2014

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

A Phase 4 interventional study of Rescue Intravitreal Aflibercept Injection and Rescue Therapy with PDT, Laser or Intravitreal Steroids in Neovascular Polypoidal Choroidal Vasculopathy, sponsored by Southeast Retina Center, Georgia. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-15.

Sponsored by Southeast Retina Center, Georgia · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.

Planned enrollment
3rd of 12
20 · median 20
Started
2014
with 1 other
Phase 4
2 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
3 of 13
Southeast Retina Center, Georgia

Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 2 in phase 4, and was the 10th registered.

Polypoidal Choroidal Vasculopathy

55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.

Browse Polypoidal Choroidal Vasculopathy studies →

Open to participants now

1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.

Read the detailed description

This is an open-label, non-randomized, unmasked, study of IAI in patients with choroidal neovascularization secondary to polypoidal choroidal vasculopathy (PCV). Twenty treatment naïve and previously treated PCV eyes will be enrolled (only one study eye per patient will be enrolled). A maximum of 10 previously treated eyes will be enrolled. Consented, enrolled patients will be followed monthly. All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months. Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met. Starting at Month 3, patients can receive non-anti vascular endothelial growth factor (VEGF) rescue therapy (ie: Photodynamic Therapy (PDT), laser, intravitreal steroids) if the pre-defined criteria are met.

03

Conditions studied

  • Neovascular Polypoidal Choroidal Vasculopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 18 years of age. Females of child bearing potential will undergo urine pregnancy testing and be required to use appropriate methods of
  • ICG and fluorescein angiographic characteristics consistent with active, leaking PCV with subfoveal lesions and/or subfoveal hemorrhage, lipid exudates, PED or fluid
  • Best corrected early treatment of diabetic retinopathy study (ETDRS) visual acuity at 4 meters between 20/20 - 20/400 (BCVA ETDRS letter score 85 - 20 letters in the study eye)
  • Lesion Characteristics - leaking lesions consistent with PCV. (No limitations on hemorrhage, fibrosis or atrophy)
  • Clear ocular media to allow for photography/angiography
  • Willing and able to comply with clinic visits and study-related procedures
  • Patients with bilateral disease will only be able to enroll one eye
  • Provide signed

Exclusion criteria

Exclusion Criteria:

  • Any history of systemic Anti-VEGF therapy
  • Current ocular or periocular infection
  • Active intraocular inflammation
  • Any comorbid condition that may decrease visual acuity
  • Any patients who have had intraocular surgery within the past 30 days for any condition
  • For treatment naïve patients: No prior anti-VEGF, PDT, intravitreal or laser (subfoveal or non foveal)
  • For previously-treated patients :
  • Prior anti-VEGF (ranibizumab, bevacizumab, pegaptanib) within 30 days
  • Prior IAI
  • Prior PDT , transpupillary thermal therapy (TTT) or radiation within 90 days (a maximum of 3 PDTs allowed)
  • Prior intravitreal steroids within 90 days
  • Prior non-foveal laser within 90 days
  • Prior subfoveal laser
  • Patients with features of dry age-related macular degeneration such as abundant drusen and symptoms/demographic features inconsistent with the diagnosis of PCV
  • Allergy to fluorescein, ICG, iodine, shellfish
  • Any other condition that the investigator believes would pose a significant hazard to the patient if the therapy were initiated
  • Participation in another simultaneous medical investigation or trial
  • History of previous subfoveal laser
  • Advanced glaucoma (IOP > 25 or cup/disc ratio > 0.8)
  • Pregnant or breast-feeding women
  • Sexually active men* or women of ** who are unwilling to practice adequate during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. ** women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Intravitreal Aflibercept Injection

    All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.

    Drug: Rescue Intravitreal Aflibercept Injection · Procedure: Rescue Therapy with PDT, Laser or Intravitreal Steroids

Interventions

  • DrugRescue Intravitreal Aflibercept Injection

    Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.

  • ProcedureRescue Therapy with PDT, Laser or Intravitreal Steroids

    Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity

    The primary objective of the study is the incidence and severity of ocular and systemic adverse events at Month 6.

    Time frame: Month 6

  2. Incidence and Severity

    The primary objective of the study is the incidence and severity of ocular and systemic adverse events at Month 12.

    Time frame: Month 12

Secondary outcomes

  1. Change in Best Corrected Visual Acuity (BCVA)

    •The mean change in BCVA from Baseline to Month 6 and from Baseline up to 12 months

    Time frame: Months 6 and 12

  2. Change in Best Corrected Visual Acuity (BCVA)

    •Proportion of patients gaining 5, 10 and 15 letters at Months 6 and 12

    Time frame: Months 6 and 12

  3. Change in Best Corrected Visual Acuity (BCVA)

    •Proportion of patients losing 5,10, and 15 letters at Months 6 and 12

    Time frame: Months 6 and 12

  4. Photography Assessments

    •Mean change from baseline in central subfield thickness at Months 6 and 12 as assessed on spectral domain optical coherence tomography (SD-OCT)

    Time frame: Months 6 and 12

  5. Photography Assessments

    •Mean change from baseline in macular volume at Months 6 and 12 as assessed on SD-OCT

    Time frame: Months 6 and 12

  6. Photography Assessments

    •Mean change from baseline in choroidal thickness at Months 6 and 12 through SD-OCT

    Time frame: Months 6 and 12

  7. Photography Assessments

    •Proportion of patients with no evidence of pigment epithelial detachment (PED), intraretinal and subretinal fluid from choroidal neovascularization (CNV) as assessed by optical coherence tomography (OCT) at 6 and 12 months

    Time frame: Months 6 and 12

  8. Photography Assessments

    •Mean change from baseline in the total area of CNV fluorescein angiographic leakage at months 6 and 12

    Time frame: Months 6 and 12

  9. Photography Assessments

    •Fluorescein angiograms, indocyanine green (ICG) angiograms, OCT and fundus photographs at Months 6 and 12 compared to baseline as unchanged, resolved, improved, worsened, or cannot determine. See section 9.1.2.2

    Time frame: Months 6 and 12

  10. Photography Assessments

    •Rate of polyp regression and resolution at 6 and 12 Months

    Time frame: Months 6 and 12

Other outcomes

  1. Rescue Therapy

    •Mean number of injections of IAI

    Time frame: Month 12

  2. Rescue Therapy

    •Incidence of need and administration of rescue therapy with PDT, laser, or intravitreal steroids

    Time frame: Month 12

  3. Rescue Therapy

    •Incidence and need of administration of additional IAI therapy

    Time frame: Month 12

07

Study locations

1 of 1 sites recruiting
  • Southeast Retina Center, PC
    Augusta, Georgia 30909, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Mar 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2014
First posted
Mar 20, 2014
Start
Mar 2014
Primary completionEst.
Mar 2015
CompletionEst.
Mar 2016
Last update
Oct 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02092532
Lead sponsor
Southeast Retina Center, Georgia
Responsible party
Sponsor
First posted
Mar 20, 2014
Start date
Mar 2014
Primary completion
Mar 2015 (estimated)
Completion
Mar 2016 (estimated)
Last update
Oct 15, 2014

Study contacts

Siobhan Ortiz
Contact
siobhan@southeastretina.com
706-650-0061
Dennis M Marcus, MD
principal investigator · Part-Owner of Southeast Retina Center, PC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion